Thus, overall, we observed that β-catenin inhibition alone for CTNNB1-mutated HCC is most effective in early-stage disease setting as evident through significant tumor responses in multiple models of CTNNB1-mutated HCC, and as partial responses in β-catenin non-mutated HCC models. The gene discussed is CTNNB1; the disease is neoplasm.